Lineage Cell Therapeutics Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing novel cell therapies for unmet medical needs. The company leverages a proprietary cell-based therapy platform to generate terminally differentiated human cells from pluripotent and progenitor starting materials, with the aim of replacing or supporting cells affected by degenerative disease or traumatic injury, or bolstering immune responses against cancer. Based in Carlsbad, California, Lineage maintains development and manufacturing capabilities to advance its cell therapies and related products. It operates as a small to mid-sized biotechnology enterprise.

Its clinical assets include OpRegen, a retinal pigment epithelium transplant in Phase I/IIa for dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa for acute spinal cord injuries; and VAC2, an allogeneic dendritic cell immunotherapy in Phase I for non-small cell lung cancer. In March 2026, the company announced the launch of a preclinical COR1 program for corneal endothelial disease.

Sign up for free to view info

Company overview Employee directory